CA2503310A1 - Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking - Google Patents
Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking Download PDFInfo
- Publication number
- CA2503310A1 CA2503310A1 CA002503310A CA2503310A CA2503310A1 CA 2503310 A1 CA2503310 A1 CA 2503310A1 CA 002503310 A CA002503310 A CA 002503310A CA 2503310 A CA2503310 A CA 2503310A CA 2503310 A1 CA2503310 A1 CA 2503310A1
- Authority
- CA
- Canada
- Prior art keywords
- thc
- cannabis
- decarboxylation
- flowers
- conversion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pyrane Compounds (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
A method is described whereby the latent cannabinoids in the cannabis plant (sativa or indiga) can be activated to make them more efficacious as an orally administered medicine or for sublingual, suppository or patch applications. The process described is primarily a decarboxylation of the acid form of a number of cannabinoid molecules to the alcohol moiety. This decarboxylation step is performed by heating the ground cannabis leaves and flowers for a specific time- period and temperature in a custom designed container. The decarboxylation of Tetrahydrocannabinolic Acid (THC-A) to Delta-9 Tetrohydrocannabinol (THC) transforms the THC-A from a compound with no known physiological activity to THC with very well characterized immune, anti-inflammatory and psycho-activity. Similarly, the decarboxylation of cannabidiolic acid to cannabidiol activates these molecules that, in turn, is thought to modulate the effects of THC. These activated compounds are now useful for making standardized dosages of cannabis medicine. The resultant preparations from this process can be used in either oral, sublingual, suppository or patch administrations.
Description
Background to the Invention:
Patent No. ZA200306794 speaks of an invention that ultilises organic solvents to prepare extracts from cannabis. This patent uses no organic solvent or extraction procedure in its formulation.
Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
Patent No. US2003191180 speaks again of organic solvent extraction of cannabinoids from plant material plus the use of the invention for synthetic analogues. The patent described here references only natural product material and no organic solvent is required for extraction.
Patent No. W003063847 teaches an anti-nausea formulation based on solvent extraction of THC-A. In the patent described here no extraction proceeds activation of THC-A
to THC.
Patent No. US2002086438 again teaches an organic solvent extraction of cannabinoids to be used in medicinal formulations. This patent describes the use of no organic solvent and any stage in the preparation of the product.
Cannabis (Sativa and Indiga) has been used for many thousands of years as medicine to treat a multitude of ailments from arthritis to multiple sclerosis. For the most part the administrative route has been in the smoked form. By burning the dried cannabis leaves and flowers the medicinal compounds within the plant matrix become activated and hence elicit their physiological effects. If the cannabis is not heated as in smoking or baking into brownies, the THC is not activated and the medicinal properties of the cannabinoids do not present.
Heating of cannabis to activate the major cannbinoid constituents must be done within a rather narrow temperature window. Not heating the cannabis enough will allow only partial conversion of the acids to the alcohols, heating too much will cause conversion and subsequent loss of the converted cannabinoids to atmosphere through vaporization.
With the invention described here, one can take a known weight of cannabis plant, place it in a special container, heat the container and cannabis for a set time at a specified temperature and accomplish the same degree of conversion each time.
This reproducible conversion method allows the creation of standardized cannabis medicine, with known dosages, that can be used for oral applications.
The standardization of cannabis medicine for oral administration requires two analytical steps. One must determine the concentration of the THC-A in the starting raw material before grinding and conversion. This pre-determination of THC-A allows for better adjustment of the subsequent heating temperature to be applied to the preparation.
More importantly, identification and quantification of the individual cannabinoids in the post-heating mixture is not only vital to the standardization process, but is also required to note the percentage conversion of THC-A to THC. If conversion is not complete, temperature can be reapplied until conversion optimized per unit time. If however, the sample has been over-heated then the THC concentration in the finished product will be lower because of burn-off and cannot be recovered.
The design of the container for holding the cannabis during heating is also paramount to the efficiency of conversion. Optimally, conversion should mean the removal of carbon dioxide from the acidic cannabinoids and little else. Since the heating process will vaporize other low molecular weight and boiling point compounds that may also be therapeutic, loss of these compounds is to be avoided. As stated previously, the optimal conversion removes only C02. 'The container design is such that optimum efficiency is achieved.
The THC level of the converted cannabis can also be modulated by this method.
That is an exact concentration of THC can be achieved in each preparation, by adjusting the heating time interval. By utitilizing, this method the THC to THC-A ratio can be adjusted to any desired level be using specified temperature and time settings. Thus, specific dosages of THC can be achieve within a raw material, making the formulation of standardized products more feasible and cost efficient.
Objectives of the Invention:
1.) An objective of this invention is to allow reproducible conversions of quantifiable amounts of cannabinoid acids in cannabis leaves and flowers to equivalent amounts of their individual alcohols.
Patent No. ZA200306794 speaks of an invention that ultilises organic solvents to prepare extracts from cannabis. This patent uses no organic solvent or extraction procedure in its formulation.
Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
Patent No. US2003191180 speaks again of organic solvent extraction of cannabinoids from plant material plus the use of the invention for synthetic analogues. The patent described here references only natural product material and no organic solvent is required for extraction.
Patent No. W003063847 teaches an anti-nausea formulation based on solvent extraction of THC-A. In the patent described here no extraction proceeds activation of THC-A
to THC.
Patent No. US2002086438 again teaches an organic solvent extraction of cannabinoids to be used in medicinal formulations. This patent describes the use of no organic solvent and any stage in the preparation of the product.
Cannabis (Sativa and Indiga) has been used for many thousands of years as medicine to treat a multitude of ailments from arthritis to multiple sclerosis. For the most part the administrative route has been in the smoked form. By burning the dried cannabis leaves and flowers the medicinal compounds within the plant matrix become activated and hence elicit their physiological effects. If the cannabis is not heated as in smoking or baking into brownies, the THC is not activated and the medicinal properties of the cannabinoids do not present.
Heating of cannabis to activate the major cannbinoid constituents must be done within a rather narrow temperature window. Not heating the cannabis enough will allow only partial conversion of the acids to the alcohols, heating too much will cause conversion and subsequent loss of the converted cannabinoids to atmosphere through vaporization.
With the invention described here, one can take a known weight of cannabis plant, place it in a special container, heat the container and cannabis for a set time at a specified temperature and accomplish the same degree of conversion each time.
This reproducible conversion method allows the creation of standardized cannabis medicine, with known dosages, that can be used for oral applications.
The standardization of cannabis medicine for oral administration requires two analytical steps. One must determine the concentration of the THC-A in the starting raw material before grinding and conversion. This pre-determination of THC-A allows for better adjustment of the subsequent heating temperature to be applied to the preparation.
More importantly, identification and quantification of the individual cannabinoids in the post-heating mixture is not only vital to the standardization process, but is also required to note the percentage conversion of THC-A to THC. If conversion is not complete, temperature can be reapplied until conversion optimized per unit time. If however, the sample has been over-heated then the THC concentration in the finished product will be lower because of burn-off and cannot be recovered.
The design of the container for holding the cannabis during heating is also paramount to the efficiency of conversion. Optimally, conversion should mean the removal of carbon dioxide from the acidic cannabinoids and little else. Since the heating process will vaporize other low molecular weight and boiling point compounds that may also be therapeutic, loss of these compounds is to be avoided. As stated previously, the optimal conversion removes only C02. 'The container design is such that optimum efficiency is achieved.
The THC level of the converted cannabis can also be modulated by this method.
That is an exact concentration of THC can be achieved in each preparation, by adjusting the heating time interval. By utitilizing, this method the THC to THC-A ratio can be adjusted to any desired level be using specified temperature and time settings. Thus, specific dosages of THC can be achieve within a raw material, making the formulation of standardized products more feasible and cost efficient.
Objectives of the Invention:
1.) An objective of this invention is to allow reproducible conversions of quantifiable amounts of cannabinoid acids in cannabis leaves and flowers to equivalent amounts of their individual alcohols.
2.) A further objective of this invention is to allow activation of specific cannabinoid compounds by a heating/decarboxylation method that allows high yields of the activated cannabinoids.
3.) A further objective is to provide a method whereby formerly non-psycho-active cannabinoids are decarboxylated to their psycho-active moiety and hence become useful in the treatment of symptoms of many ailments.
4.) A further objective is to provide a method whereby the THC content of a therapeutic sample can be modulated to achieve a specific dosage of said active in a standardized formula.
5.) A further objective of this invention is to provide a means of standardizing cannabis medicines with known dosages of active THC per gram of raw material. Since the degree of conversion by the described method can be determined by High Pressure Liquid Chromatography (HPLC) in a raw material preparation a fixed dosage can be made and the product standardized.
6.) A further objective is to allow production of activated standardized raw material for use in oral, sublingual, suppository or patch applications.
7.) A further objective is to produce formulations without the use of organic solvents or supercritical fluids to extract cannabinoids from plant material.
Summary of the Invention:
Described here is a method/process whereby the medicinal compounds contained in cannabis plant material (leaves and flowers) are activated to be useful for administrative routes other than smoking. Such an application also allows for the standardization of the converted material into known dosages of activated THC.
Summary of the Invention:
Described here is a method/process whereby the medicinal compounds contained in cannabis plant material (leaves and flowers) are activated to be useful for administrative routes other than smoking. Such an application also allows for the standardization of the converted material into known dosages of activated THC.
Claims
Claims:
What is claimed:
Claim 1: A process for converting the flowers and leaves of the cannabis plant (flowers and leaves) by specific heating, time and containment protocols yields a product that is amenable to standardization and administrative routes other than smoking.
A method of claim 1 whereby cannabis material (leaves and flowers) is ground to a mesh size that allows for consistent heating.
A method of claim 2 whereby ground cannabis material is heated to a specific temperature to allow conversion (de-carboxylation).
A method of claim 3 whereby heated ground cannabis material is kept at a specific temperature for a specific time to allow optimal conversion of the THC-A to THC.
A method of claim 4 whereby the percentage conversion of the THC-A to THC can be optimized to allow maximum efficiency and efficacy in the finished product.
A method of claim 5 whereby the concentration of converted THC can be determined and thus allow standardization of cannabis in to known dosages of active THC.
A method of claim 6 whereby the standardized cannabis can be used as medicines administered orally, in a sublingual fashion, as a suppository or in a patch.
What is claimed:
Claim 1: A process for converting the flowers and leaves of the cannabis plant (flowers and leaves) by specific heating, time and containment protocols yields a product that is amenable to standardization and administrative routes other than smoking.
A method of claim 1 whereby cannabis material (leaves and flowers) is ground to a mesh size that allows for consistent heating.
A method of claim 2 whereby ground cannabis material is heated to a specific temperature to allow conversion (de-carboxylation).
A method of claim 3 whereby heated ground cannabis material is kept at a specific temperature for a specific time to allow optimal conversion of the THC-A to THC.
A method of claim 4 whereby the percentage conversion of the THC-A to THC can be optimized to allow maximum efficiency and efficacy in the finished product.
A method of claim 5 whereby the concentration of converted THC can be determined and thus allow standardization of cannabis in to known dosages of active THC.
A method of claim 6 whereby the standardized cannabis can be used as medicines administered orally, in a sublingual fashion, as a suppository or in a patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002503310A CA2503310A1 (en) | 2005-04-08 | 2005-04-08 | Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002503310A CA2503310A1 (en) | 2005-04-08 | 2005-04-08 | Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2503310A1 true CA2503310A1 (en) | 2006-10-08 |
Family
ID=37101404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002503310A Abandoned CA2503310A1 (en) | 2005-04-08 | 2005-04-08 | Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2503310A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069763A3 (en) * | 2013-11-05 | 2015-10-08 | First Watersign Llc | Sublingual cannabis dosage form and methods of making and using the same |
| US20150352044A1 (en) * | 2014-06-06 | 2015-12-10 | CannTrust Inc. | Single serve beverage pod containing cannabis |
| WO2016064987A1 (en) * | 2014-10-21 | 2016-04-28 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| IT201800010262A1 (en) * | 2018-11-12 | 2020-05-12 | Kyvaris Pharma Srls | Formulation in macro-granules based on therapeutic cannabis and related production method |
| US12070479B1 (en) | 2021-04-19 | 2024-08-27 | PT Worldwide | Decarboxylated cannabis compositions and methods of making the same |
-
2005
- 2005-04-08 CA CA002503310A patent/CA2503310A1/en not_active Abandoned
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069763A3 (en) * | 2013-11-05 | 2015-10-08 | First Watersign Llc | Sublingual cannabis dosage form and methods of making and using the same |
| US20150352044A1 (en) * | 2014-06-06 | 2015-12-10 | CannTrust Inc. | Single serve beverage pod containing cannabis |
| US9480647B2 (en) * | 2014-06-06 | 2016-11-01 | CannTrust Inc. | Single serve beverage pod containing cannabis |
| US10758481B2 (en) | 2014-06-06 | 2020-09-01 | CannTrust Inc. | Single serve beverage pod containing cannabis |
| US11628142B2 (en) | 2014-06-06 | 2023-04-18 | CannTrust Inc. | Single serve beverage pod containing cannabis |
| WO2016064987A1 (en) * | 2014-10-21 | 2016-04-28 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US9730911B2 (en) | 2014-10-21 | 2017-08-15 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US10555928B2 (en) | 2014-10-21 | 2020-02-11 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| US11291650B2 (en) | 2014-10-21 | 2022-04-05 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
| IT201800010262A1 (en) * | 2018-11-12 | 2020-05-12 | Kyvaris Pharma Srls | Formulation in macro-granules based on therapeutic cannabis and related production method |
| US12070479B1 (en) | 2021-04-19 | 2024-08-27 | PT Worldwide | Decarboxylated cannabis compositions and methods of making the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10537592B2 (en) | Decarboxylated cannabis resins, uses thereof and methods of making same | |
| Vinatoru | An overview of the ultrasonically assisted extraction of bioactive principles from herbs | |
| EP2844243B1 (en) | Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol | |
| Pongprayoon et al. | Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of Zingiber cassumunar. Part I: The essential oil | |
| US20170333503A1 (en) | Process for extraction, separation and purification of cannabinoids, flavonoids and terpenes from cannabis | |
| JP2005512943A5 (en) | ||
| Kumar et al. | Fostered antiarthritic upshot of moringa oleifera lam. stem bark extract in diversely induced arthritis in wistar rats with plausible mechanism | |
| WO2010034971A2 (en) | Sub-critical water extraction of medicinal plants | |
| CN102961282B (en) | Composition with penetration enhancing effect as well as preparation method and application thereof | |
| CA2503310A1 (en) | Method of activation of cannabis to render standardized preparations for therapeutic administration, other than smoking | |
| EA030607B1 (en) | Process for making extracts of plants of the scrophulariaceae family of the genus picrorhiza and use thereof for prevention and treatment of diseases caused by dna viruses | |
| Velázquez et al. | Anti-diarrheal activity of (–)-Epicatechin from Chiranthodendron pentadactylon Larreat: Experimental and computational studies | |
| Jia et al. | Anti-inflammatory effects of an herbal medicine (Xuan-Ju agent) on carrageenan-and adjuvant-induced paw edema in rats | |
| Melnyk et al. | Skin microbiota metabolism of natural products from comfrey root (Symphytum officinale L.) | |
| Bapat et al. | Bio-analytical studies on the process of detoxification and safety evaluation of Aconitum laciniatum and Abrus precatorius for use in ayurvedic preparations | |
| CN113750163A (en) | Artemisia annua essential oil and white tea essential oil for treating acne and composition thereof | |
| CN100417410C (en) | Medicine for treating gastrointestinal summer damp cold and preparing method thereof | |
| Sultan et al. | Pharmacognostic and phytochemical investigation of aerial parts of Centella asiatica Linn | |
| CN112755058B (en) | Application of devilpepper ethanol extract in preparation of medicine for relaxing and pre-contracting tracheal smooth muscle | |
| Yang et al. | Studies on chemical constituents in rhizome of Matteuccia struthiopteris | |
| Nandakumar et al. | Phytochemical Analysis and Cellular Uptake Study of an Ayurvedic Formulation, Vyaghryadi Kashayam Used in the Clinical Management of COVID-19. | |
| Christi et al. | Phytochemical Study on the Extract of Scoparia dulcis LINN. Leaves | |
| JP3162335B2 (en) | Botanicals for the treatment of cutaneous fungal infections, their production and use | |
| Sivanandan et al. | PHARMACOGNOSTICAL AND PHYSICO-CHEMICAL ANALYSIS OF SHATAVARYADI KSHEERAPAKA-A POLYHERBAL MILK-BASED FORMULATION FOR THE MANAGEMENT OF MENOPAUSAL SYNDROME | |
| Aliyu et al. | Molecular Docking of Phytocompounds from Mentha Piperita Leaf Extract as Promising Inhibitory Agents against Candida Albicans’s Glucosamine-6-Phosphate Synthase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20071024 |